About Cabling Installation & Maintenance

Our mission: Bringing practical business and technical intelligence to today's structured cabling professionals

For more than 30 years, Cabling Installation & Maintenance has provided useful, practical information to professionals responsible for the specification, design, installation and management of structured cabling systems serving enterprise, data center and other environments. These professionals are challenged to stay informed of constantly evolving standards, system-design and installation approaches, product and system capabilities, technologies, as well as applications that rely on high-performance structured cabling systems. Our editors synthesize these complex issues into multiple information products. This portfolio of information products provides concrete detail that improves the efficiency of day-to-day operations, and equips cabling professionals with the perspective that enables strategic planning for networks’ optimum long-term performance.

Throughout our annual magazine, weekly email newsletters and 24/7/365 website, Cabling Installation & Maintenance digs into the essential topics our audience focuses on.

  • Design, Installation and Testing: We explain the bottom-up design of cabling systems, from case histories of actual projects to solutions for specific problems or aspects of the design process. We also look at specific installations using a case-history approach to highlight challenging problems, solutions and unique features. Additionally, we examine evolving test-and-measurement technologies and techniques designed to address the standards-governed and practical-use performance requirements of cabling systems.
  • Technology: We evaluate product innovations and technology trends as they impact a particular product class through interviews with manufacturers, installers and users, as well as contributed articles from subject-matter experts.
  • Data Center: Cabling Installation & Maintenance takes an in-depth look at design and installation workmanship issues as well as the unique technology being deployed specifically for data centers.
  • Physical Security: Focusing on the areas in which security and IT—and the infrastructure for both—interlock and overlap, we pay specific attention to Internet Protocol’s influence over the development of security applications.
  • Standards: Tracking the activities of North American and international standards-making organizations, we provide updates on specifications that are in-progress, looking forward to how they will affect cabling-system design and installation. We also produce articles explaining the practical aspects of designing and installing cabling systems in accordance with the specifications of established standards.

Cabling Installation & Maintenance is published by Endeavor Business Media, a division of EndeavorB2B.

Contact Cabling Installation & Maintenance

Editorial

Patrick McLaughlin

Serena Aburahma

Advertising and Sponsorship Sales

Peter Fretty - Vice President, Market Leader

Tim Carli - Business Development Manager

Brayden Hudspeth - Sales Development Representative

Subscriptions and Memberships

Subscribe to our newsletters and manage your subscriptions

Feedback/Problems

Send a message to our general in-box

 

Moderna (MRNA) Stock Trades Up, Here Is Why

MRNA Cover Image

What Happened?

Shares of biotechnology company Moderna (NASDAQ: MRNA) jumped in the afternoon session after the company presented promising early data for its investigational cancer antigen therapy, mRNA-4359, from a Phase I/II study. 

The therapy, when used alongside Merck's Keytruda, showed positive results in melanoma patients. Data presented at the European Society for Medical Oncology Congress revealed a 24% objective response rate, which measures tumor shrinkage. The rate of response increased significantly to 67% in a subgroup of patients whose tumors were positive for the PD-L1 biomarker. Furthermore, the study recorded a 60% disease control rate, meaning patients either saw their tumors shrink or their disease stabilize. The company also noted that the therapy had a manageable safety profile.

Contributing to the positive momentum, the major indices rebounded as signs of easing trade tensions between the U.S. and China emerged over the weekend.

The tech-focused Nasdaq Composite jumped around 1.7%, while the S&P 500 gained 1.2%. This rebound follows a significant sell-off the previous trading day, which saw the Nasdaq plummet 3.6% and the S&P 500 sink 2.7% after threats of new tariffs heightened fears of a trade war. Investor sentiment improved after the U.S. President adopted a more conciliatory tone toward Beijing in a social media post. The shift in language helped calm market jitters and spurred a broad-based rally as investors welcomed the potential de-escalation of the trade dispute.

After the initial pop the shares cooled down to $27.00, up 0.5% from previous close.

Is now the time to buy Moderna? Access our full analysis report here.

What Is The Market Telling Us

Moderna’s shares are extremely volatile and have had 52 moves greater than 5% over the last year. In that context, today’s move indicates the market considers this news meaningful but not something that would fundamentally change its perception of the business.

The previous big move we wrote about was 3 days ago when the stock dropped 3.5% on the news that worries over worsening trade relations with China were triggered by critical comments from President Donald Trump. The president's tone and the suggestion of canceling a meeting with President Xi caused a rapid sell-off in the market. The trade dispute flared up after China imposed export controls on rare earth minerals, which are critical components for high-tech manufacturing. The escalation of the trade war raises concerns about supply chain disruptions and increased costs for technology companies, which are heavily reliant on global trade, leading to a broad sell-off in the sector.

Moderna is down 35.7% since the beginning of the year, and at $27.00 per share, it is trading 53.2% below its 52-week high of $57.73 from October 2024. Investors who bought $1,000 worth of Moderna’s shares 5 years ago would now be looking at an investment worth $344.81.

Do you want to know what moves the business you care about? Add them to your StockStory watchlist and every time a stock significantly moves, we provide you with a timely explanation straight to your inbox. It’s free for active Edge members and will only take you a second.

More News

View More

Recent Quotes

View More
Symbol Price Change (%)
AMZN  217.75
-4.28 (-1.93%)
AAPL  256.62
-6.15 (-2.34%)
AMD  226.07
-11.96 (-5.02%)
BAC  50.60
-0.92 (-1.79%)
GOOG  251.29
-0.05 (-0.02%)
META  726.27
-7.00 (-0.95%)
MSFT  520.58
+2.92 (0.56%)
NVDA  177.51
-3.65 (-2.01%)
ORCL  271.30
-3.85 (-1.40%)
TSLA  432.56
-10.04 (-2.27%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.